Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention

A PCORI Funding Announcement (PFA) will open on May 2, 2023 to fund studies that compare the effectiveness of pharmacologic and/or non-pharmacologic interventions that address migraine prevention.

Question of Interest

What is the comparative effectiveness of novel pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine?​


Individuals who suffer from migraines. Subgroups of particular interest include patients for whom prior preventive treatments have failed; patients with comorbidities including cardiovascular disease; various migraine types (medication overuse, episodic/chronic migraine, migraine with aura); and menstrual-associated migraine.


Head-to-head comparisons of evidence-based interventions that target migraine prevention.


Frequency, severity, and duration of migraine attacks, functional impairment, quality of life, adverse events, health resource utilization, relevant caregiver outcomes, and related outcomes.


  • Total allocated for this PFA: Up to $40 million (not inclusive of intervention cost coverage)
  • Total direct funding: $10 million (not inclusive of intervention cost coverage)

Maximum project duration

Five years.

Important dates

May 2 – Applications open
May 16 – Town Hall
May 31 – Letters of Intent due
August 29 – Applications due
November 2023 – Merit review
March 2024 – Awards announced
July 2024 – Earliest start date

For more information or to request a brief consultation, please contact Leslie MacGregor, PCORI Funding Specialist: